Skip to main content
토론으로 돌아가기

생물제약 산업과 사회

Healthcare
United States
April 22, 2026에 시작됨

The Bio-Pharma Industry and Society Listing Summary Please join the CSIS Global Health Policy Center on March 17, from 10:00am – 11:30am, for an exploration of how private bio-pharmaceutical firms can better support the critically important societal goals of improved affordability, access, quality, and innovation. Drupal Admin Thu, 03/03/2016 - 15:36 Featured Image Image Contributors J. Stephen Morrison Downloads Download Transcript Here Document 160317_The_Bio-Pharma_Industry_and_Society_Tra...

출처 기사

The Bio-Pharma Industry and Society

CSIS (United States) | Mar 03, 2016

진술 추가 분석 0/5
Need to find a specific claim? Search all statements.
🗳️ Join the conversation
5 투표할 진술 • Your perspective shapes the analysis
📊 Progress to Consensus Analysis Need: 7+ participants, 20+ votes, 3+ votes per statement
Participants 0/7
Statements (7+ recommended) 5/7
Total Votes 0/20
💡 Progress updates live here. Final readiness is confirmed when all three requirements are met.

Your votes count

No account needed — your votes are saved and included in the consensus analysis. Create an account to track your voting history and add statements.

CLAIM 게시자: will • Apr 22, 2026
바이오제약 산업은 부자뿐만 아니라 모든 사람이 생명을 구하는 의약품에 접근할 수 있도록 약가 부담과 접근성을 우선시해야 한다.
AI 번역 · 원문 보기

The bio-pharma industry must prioritize affordability and access to ensure that life-saving medications are available to all, not just the wealthy.

Vote options for this statement: agree, disagree, or unsure
💬 토론 보기
Be first to respond
Vote to see results
CLAIM 게시자: will • Apr 22, 2026
혁신이 중요하지만, 바이오제약 부문의 무분별한 이윤 추구는 종종 의약품 가격 상승으로 이어지며, 공중보건을 훼손한다.
AI 번역 · 원문 보기

While innovation is crucial, the relentless pursuit of profit in the bio-pharma sector often leads to inflated drug prices, undermining public health.

Vote options for this statement: agree, disagree, or unsure
💬 토론 보기
Be first to respond
Vote to see results
CLAIM 게시자: will • Apr 22, 2026
바이오제약 산업의 빠른 혁신 추구는 의약품의 품질과 안전성을 훼손할 수 있으며, 환자에게 위험을 초래한다.
AI 번역 · 원문 보기

The focus on rapid innovation in the bio-pharma industry can compromise the quality and safety of medications, posing risks to patients.

Vote options for this statement: agree, disagree, or unsure
💬 토론 보기
Be first to respond
Vote to see results
CLAIM 게시자: will • Apr 22, 2026
바이오제약 부문의 공공-민간 파트너십은 연구 개발을 강화할 수 있으며, 사회 전체에 이익을 주는 혁신을 이끌어낼 수 있다.
AI 번역 · 원문 보기

Public-private partnerships in the bio-pharma sector can enhance research and development, leading to breakthroughs that benefit society as a whole.

Vote options for this statement: agree, disagree, or unsure
💬 토론 보기
Be first to respond
Vote to see results
CLAIM 게시자: will • Apr 22, 2026
균형 잡힌 접근이 필요하다. 바이오제약 산업은 혁신을 주도하면서 동시에 접근성과 약가 부담 문제를 해결할 수 있다.
AI 번역 · 원문 보기

A balanced approach is necessary; the bio-pharma industry can drive innovation while also addressing issues of access and affordability.

Vote options for this statement: agree, disagree, or unsure
💬 토론 보기
Be first to respond
Vote to see results

💡 How This Works

  • • Add Statements: Post claims or questions (10-500 characters)
  • • Vote: Agree, Disagree, or Unsure on each statement
  • • Respond: Add detailed pro/con responses with evidence
  • • Consensus: After enough participation, analysis reveals opinion groups and areas of agreement

Society Speaks is open and independent. Your support keeps civic discussion free from advertising and commercial influence.

Support us